Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relacorilant - Corcept Therapeutics

Next Previous
X
Search
Drug Profile

Relacorilant - Corcept Therapeutics

Alternative Names: CORT-125134

Latest Information Update: 31 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Developer Corcept Therapeutics; University of Chicago
  • Class Antineoplastics; Fluorine compounds; Isoquinolines; Ketones; Organic sulfur compounds; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cushing syndrome; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Phase II Adenocarcinoma; Prostate cancer
  • Phase I/II Solid tumours
  • No development reported Adrenocortical carcinoma

Most Recent Events

  • 28 May 2024 Efficacy and adverse events data from a phase III GRACE trial in Cushing syndrome released by Corcept Therapeutics
  • 22 Apr 2024 Efficacy and adverse events data from a phase III GRACE trial in Cushing syndrome released by Corcept Therapeutics
  • 15 Apr 2024 Corcept Therapeutics completes the phase III GRACE trial in Cushing syndrome in Netherlands, Poland, Spain, Austria, Germany, Canada, Romania and the USA (PO) (NCT03697109) (EudraCT2018-003096-35)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top